EVO ICL Lenses

EVO ICL™ Lens at Milwaukee Eye Care

If you’re tired of reaching for glasses or contacts every day, EVO ICL might be the solution you’ve been looking for. Dr. Jason Edmonds, our experienced cornea specialist, now offers this safe and effective procedure right here in Milwaukee.

What is EVO ICL?

EVO ICL is a soft lens that your doctor places inside your eye. It corrects nearsightedness, with or without astigmatism, and unlike some other vision correction options, the EVO ICL is an additive technology that corrects vision without the removal of corneal tissue and can be removed by your eye doctor if needed

How EVO ICL Works

  • EVO ICL is an outpatient procedure performed at Envision Surgery Center
  • Procedures on both eyes are typically done on the same day
  • We use numbing eye drops IV sedation so you stay comfortable.
  • Dr. Edmonds makes a tiny opening in your cornea
  • Next, he inserts and positions the EVO ICL in front of your natural lens.
  • This process typically takes less than 20 – 30 minutes.
Step 1
Pre-Op eye exam & measurements
Step 2
Eye drops & IV sedation 
Step 3
Small opening in cornea
Step 4
EVO ICL insertion & positioning
Step 5
Post-op exams & checkups

Am I a Candidate for EVO ICL?

EVO ICL is suited for those aged 21 to 45 who have stable nearsighted prescriptions (with or without astigmatism) and healthy eyes. If you want to stop relying on glasses or contacts, this might be a good fit for you.

Benefits of Choosing EVO ICL 

  • Sharp, clear vision for people with nearsightedness ¹’²
  • Quick procedure with minimal downtime. You can usually get back to work and normal activities within a couple of days
  • Lens can’t be seen or felt
  • Removable by your eye surgeon
  • Built-in UV protection
  • Great option if you have a strong prescription, dry eyes, or thin corneas
  • 99.4% of patients surveyed would have the EVO ICL procedure again³

EVO ICL – Frequently Asked Questions 

Milwaukee Eye Care has answers to your frequently asked quests about EVO ICL (Implantable Collamer® Lens).

Unlike LASIK, which uses a laser to reshape your cornea, EVO ICL involves placing a biocompatible lens in front of your natural lens. Also, because the lens is removable, EVO ICL is often called a “reversible” procedure.

If you are between 21 and 45 years old with a moderate to high prescription, with or without astigmatism, EVO ICL could be a good fit. It’s especially helpful if you have dry eyes or cannot have LASIK. The best way to find out is to schedule a free consultation!

Yes, the lens is intended to stay in your eye permanently, but it can always be removed or replaced by your eye doctor if necessary.

You won’t be able to feel the lens once it’s in place, and no one will be able to see it. It quietly works behind the scenes, helping you enjoy clearer vision without glasses or contacts.

 Many people notice clearer vision immediately or within a day after the procedure. Your vision will usually continue to improve over the following weeks as your eyes adjust.

Insurance does not cover EVO ICL since it’s not considered medically necessary.  Our team at Milwaukee Eye Care can walk you through financing options to make your vision goals more attainable.

Interested in EVO ICL? Let’s Talk!

If you’re considering vision correction, we’re here to guide you. Book a free phone consultation with one of our refractive surgery coordinators at Milwaukee Eye Care. We’ll answer your questions, discuss your options, and help you feel confident about your next steps.

Schedule Your Free Consultation

 

 

 

¹Martínez-Plaza E, López-Miguel A, López-de la Rosa  A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.  
²Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53.
³Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.

Back to Top